Larazotide (AT-1001) Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Larazotide (AT-1001) dosing: protocols, safety, and where to buy.
Half-Life
Not established as a systemic value. Larazotide is designed to act locally in the intestinal lumen and is given orally rather than for systemic exposure (PMID: 33881350); single-dose safety, tolerance and pharmacokinetics were assessed in a phase 1b study in celiac disease subjects (PMID: 17697209)
Administration Routes
Dosage Calculator
Calculate exact dosing for Larazotide (AT-1001).
Dosing data for Larazotide (AT-1001) is being researched. Check the compound page for the latest information.
Side Effects & Safety
Contraindications
No pharmacological contraindications have been established in the published trials. Mechanism-based caution: larazotide does not treat celiac disease and does not make gluten safe to eat. In every trial, patients stayed on a gluten-free diet or were given a controlled gluten challenge under supervision, and the compound was studied as an addition to the diet, not a replacement for it (PMID: 25683116). Trial exclusion criteria in the phase 3 study covered refractory celiac disease, severe complications of celiac disease and chronic active gastrointestinal disease other than celiac disease (NCT03569007).
Frequently Asked Questions
What is the recommended Larazotide (AT-1001) dosage?
Dosage for Larazotide (AT-1001) varies by protocol. Consult a qualified healthcare provider.
How often should I take Larazotide (AT-1001)?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Larazotide (AT-1001) need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Larazotide (AT-1001) side effects?
Tolerability in trials has been close to placebo. The phase 1b study reported no increase in adverse events against placebo (PMID: 17697209). In the 86-patient gluten-challenge study, larazotide was generally well tolerated, no serious adverse events occurred, and the most common adverse events were headache and urinary tract infection (PMID: 22825365). In the 342-patient phase 2b trial, safety was comparable with placebo (PMID: 25683116). A meta-analysis of four randomized trials in 626 patients found adverse events broadly comparable between larazotide and placebo, with less gluten-related diarrhea in treated patients undergoing gluten challenge (PMID: 34339872). In the phase 2a trial in 12 children with multisystem inflammatory syndrome, no larazotide-related adverse events were reported over 24 weeks of safety follow-up (PMID: 40737433).
Where can I buy Larazotide (AT-1001)?
Compare 1 listings from 1 vendor on our price comparison page, starting from $99.99.
Larazotide (AT-1001) Full Profile
Research data, mechanisms, and pricing
Interaction Checker
Check drug & compound interactions
Related Dosage Guides
All GuidesFree 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.